Syncona — 2024 Investments

3 investments dated 2024 · listed companies and verified rows first · show all

Autolus TherapeuticsNASDAQ: AUTLFeb 2024

London

Christian Itin(Executive Officer, Director)William D. Young(Director)Edgar Braendle(Executive Officer)Martin Murphy(Director)Linda Bain(Director)Christopher Vann(Executive Officer)

Purespringpurespringtx.com in 𝕏Oct 2024

Purespring is a precision nephrology company developing podocyte-targeted gene therapies for kidney diseases, using its GlomThera platform to deliver genetic treatments directly to kidney cells.

BiotechHealthtechMedical Devices

Co-investorsSofinnova Partners British Patient Capital Forbion Gilde Healthcare

Resolution Therapeuticsresolution-tx.com in 𝕏Oct 2024 · $85M

Resolution Therapeutics develops Regenerative Macrophage Therapy, a cell therapy for patients with end-stage liver disease intended to help damaged livers recover and slow disease progression.

BiotechHealthtech

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.